0,1,2,3,4,5,6,7,8,9
Table 3. (Continued),,,,,,,,,
HPV TYPE,REgIoN,ALLELE,START,END,PEPTIDE,CoMBLIB,CoMBLIB,Smm,Smm
,,,,,,SCoRE,RANk,ALIgN,ALIgN
,,,,,,,,ic50,RANk
,II,HLa-DrB1*04:01,157,171,esaHaataVItQDVr,–,–,3466,28.8
,II,HLa-DrB1*01:01,157,171,esaHaataVItQDVr,0.08,9.62,540,47.14
,III,HLa-DrB1*01:01,194,208,eHWaKGtLCKPaQLQ,1.34,20.07,1281,63.69
,III,HLa-DrB1*04:01,194,208,eHWaKGtLCKPaQLQ,–,–,9494,50.17
,IV,HLa-DrB1*04:01,301,315,DLYIKGtsanmretP,–,–,56,0.39
,IV,HLa-DrB1*01:01,301,315,DLYIKGtsanmretP,5.09,26.48,51,10
Low risk type,,,,,,,,,
HPV11,I,HLa-DrB1*04:01,142,156,VnVGmDYKQtQLCmV,–,–,4913,35.76
,I,HLa-DrB1*01:01,142,156,VnVGmDYKQtQLCmV,791736.5,88.8,420,42.19
,II,HLa-DrB1*04:01,266,280,ePVPDDLLVKGGnnr,–,,8388,47.43
,II,HLa-DrB1*01:01,266,280,ePVPDDLLVKGGnnr,812.21,57.66,1166,61.98
,III,HLa-DrB1*04:01,304,318,fnKPYWLQKaQGHnn,,,1607,16.29
,III,HLa-DrB1*01:01,304,318,fnKPYWLQKaQGHnn,247.24,50.05,200,28.5
,IV,HLa-DrB1*04:01,350,364,tYtnsDYKeYmrHVe,–,–,13755,58.62
,IV,HLa-DrB1*01:01,350,364,tYtnsDYKeYmrHVe,14290.32,73.49,6877,87.61
,V,HLa-DrB1*04:01,419,433,sQaItCQKPtPeKeK,–,–,3608,29.58
,V,HLa-DrB1*01:01,419,433,sQaItCQKPtPeKeK,811.45,57.66,1894,70.43
